Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.